Search Results

The Light Age, Inc. Q-Clear™ Nd:YAG Laser System is intended for use in general and plastic surgery, dermatology, and podiatry for the incision, excision, vaporization of soft tissues. The Light Age, Inc. Q-Clear™ Nd: YAG Laser is indicated for the following uses:

The 1064nm wavelength is indicated for :

1. Podiatry for incision, excision, vaporization, coagulation of soft tissues including:

• Matrixectomy
• Warts including periungual, subungual, and plantar warts
• Radical nail excision
• Neuromas
• The O-Clear™ Laser System is indicated for use for the temporary increase of clear nail in patients with onychomycosis (e.g., dermatophytes Trichophyton rubrum and T. mentagrophytes, and/or yeasts Candida albicans, etc.)

2. Dermatology and Plastic Surgery for incision, excision, vaporization, coagulation of soft tissues including:

• Lesions of the skin and subcutancous tissue
• Spider veins
• Plantar Warts
• Periungual and subungual warts
• Debridement of decubitus ulcer
• Treatment of keloids

3. General Dermatology

• Dark ink tattoo removal
• Treatment of pigmented lesions (particularly Nevus of Ota)
• Removal or lightening of hair
• Skin resurfacing with or without adjuvant preparation
• Treatment of common Nevi

The 532 nm wavelength is indicated for:

1. Dermatology and Plastic Surgery for incision, excision, vaporization, coagulation of soft tissues including spider veins:
2. General Dermatology

• Removal of light ink (red, tan, purple, and orange) tattoos
• Treatment of common nevi
• Treatment of café-au-lait spots
• Treatment of seborrheic keratoses
  Treatment of vascular lesions, including facial and leg veins, telangiectasias, angiomas, hemangiomas, port wine stains, and most pigmented lesions (e.g. lentigines, and ephelides)

The Light Age Q-Clear™ laser has an Nd:YAG crystal rod as a lasing medium. Pulsed energy is emitted at 1064 nanometers in the infrared portion of the spectrum. With the frequency doubler installed, a 532nm beam is emitted. The 532nm emission is visible green light. Energy from the laser is delivered directly to the target area via the handpiece, which produces a circular beam on the skin. A red aiming beam is provided to allow the operator to precisely target the treatment area. The Q-Clear™ Laser is equipped with safety fealures in conformance with 21 CFR Part 1040.

The Q-Clear™ Nd:YAG laser system is comprised of the following main components:

• (1) Main Console consists of electrical components including
• a. Control and Display Panel with
• Keyswitch controlling access to the system and mode of operation (off, standby and ready)
• Emergency Stop Button
• Remote Interlock Connector
• Footswitch connector
• Power Cord connector
• (2) Footswitch
• (3) Medical grade power cord
• (4) Q-Switched 1064 / 532 nm Treatment Head with Nd:YAG laser rod
• (5) Long Pulsed 1064 nm Treatment Head with Nd:YAG laser rod
• (6) Delivery Devices intended for Non-Contact and contact with intact skin / tissue
• a. Handpieces
• b. Handbiece tips
• (7) Operator and Patient safety glasses and goggles
• (8) Accessories standoffs, water bottle

Here's an analysis of the provided text regarding the Light Age Q-Clear™ Nd:YAG Laser, focusing on acceptance criteria and the supporting study:

Acceptance Criteria and Reported Device Performance

The document describes the device's technical specifications and a clinical study related to a specific indication. The primary "acceptance criteria" presented here are through a comparative analysis with predicate devices for technical characteristics and through clinical study results for a specific indication.

Table 1: Acceptance Criteria (Technical Characteristics) and Reported Device Performance (as compared to predicates)

Table 2: Acceptance Criteria (Clinical) and Reported Device Performance

Study Details

The provided text details one specific clinical study related to the onychomycosis indication.

1. Sample size used for the test set and the data provenance:

   • Sample Size: 100 randomized subjects.
   • Data Provenance: Not explicitly stated, but the study design suggests a prospective clinical trial. The countries of origin are not mentioned, but the inclusion of "Caucasian, Asian, African American, and Latino" suggests a diverse population, possibly within the USA where the company is based.

2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

   • This information is not provided in the summary. The "clinically apparent diagnosis of onychomychosis" implies a medical assessment, but the number or qualifications of the diagnosing experts are not detailed.

3. Adjudication method for the test set:

   • This information is not provided. The assessment of "significant apparent clearing" and "average clearance" would typically involve some form of independent assessment, but the method (e.g., 2+1, 3+1, none) is not specified.

4. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

   • No MRMC or AI-assisted study was mentioned. This device is a laser system, not an AI diagnostic tool.

5. If a standalone (i.e. algorithm only without human-in-the loop performance) was done:

   • This is not applicable as the device is a laser for treatment, not an algorithm for diagnosis or image analysis. The clinical study evaluated the device's therapeutic effect.

6. The type of ground truth used (expert consensus, pathology, outcomes data, etc):

   • The ground truth for the diagnosis of onychomycosis was "clinically apparent diagnosis." For the effectiveness of the treatment, the ground truth was "apparent clearing" of "dystrophic toenails," which is an outcomes-based assessment presumably made by clinicians, though specific methodology for this assessment is not detailed. The text also mentions "e.g., dermatophytes Trichophyton rubrum and T. mentagrophytes, and/or yeasts Candida albicans, etc." which implies a microbiological confirmation (pathology/laboratory testing) would be part of the diagnostic process for onychomycosis, but it's not explicitly stated as the ground truth standard for the trial's enrollment or outcome measurement.

7. The sample size for the training set:

   • This is not applicable as the document describes a physical laser device and its clinical evaluation, not a machine learning algorithm that requires a training set.

8. How the ground truth for the training set was established:

   • This is not applicable as there is no training set mentioned for this type of device submission.

Ask a specific question about this device

The Light Age Q-Clear™ Laser is indicated for the following uses:

1. For incision, excision, ablation, and vaporization of soft tissue for General Dermatology
2. The 1064nm wavelength is indicated for:

• Dark ink tattoo removal
• Removal of pigmented lesions (particularly Nevus of Ota)
• Removal or lightening of hair
• Skin resurfacing with or without adjuvant preparation
• Treatment of common nevi

3. The 532nm wavelength is indicated for:

• Removal of light ink (red, tan, purple and orange) tattoos
• Treatment of common nevi
• Treatment of café-au-lait spots
• Treatment of seborrheic keratoses
• Treatment of vascular lesions, including facial and leg veins, telangiectasias, angiomas, hemangiomas, port wine stains, and most pigmented lesions (e.g. lentigines, and ephelides)

The Light Age Q-Clear™ Laser has a Nd: Y AG crystal rod as a lasing medium. Pulsed energy is emitted at 1064 nanometers in the near-infrared portion of the spectrum. With the optional frequency doubler installed, a 532nm beam is emitted. The laser is delivered directly to the target area via the handpiece, which produces a circular beam on the skin. A red aiming beam is provided to allow the operator to precisely target the treatment area. The Q-Clear™ Laser is equipped with safety features in conformance with 21CFR Part 1040.

The provided text is a 510(k) summary for the Light Age Q-Clear™ Laser. It details the device's description, intended use, and claims of substantial equivalence to predicate devices. However, it does not contain information about acceptance criteria or a study that proves the device meets specific performance criteria.

The document is a regulatory submission for premarket notification, asserting that the device is "substantially equivalent" to previously cleared devices. This type of submission often relies on demonstrating that the new device has the same technological characteristics and intended use as predicate devices, and does not raise new questions of safety or efficacy. It generally does not include detailed performance studies with acceptance criteria in the way a clinical trial or a specific analytical performance study for a diagnostic device would.

Therefore, I cannot provide the requested information from the provided text.

Specifically, the following information is not available in the provided document:

1. A table of acceptance criteria and the reported device performance: This document asserts substantial equivalence, not specific performance metrics against defined acceptance criteria.
2. Sample size used for the test set and the data provenance: No performance study is described that would have a test set.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not applicable as no ground truth for a test set is described.
4. Adjudication method for the test set: Not applicable.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done: Not applicable.
6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done: Not applicable, as this is a laser device, not an algorithm.
7. The type of ground truth used: Not applicable.
8. The sample size for the training set: Not applicable.
9. How the ground truth for the training set was established: Not applicable.

The document's statement regarding safety and effectiveness is: "The Light Age Q-Clear™ Laser has the same wavelengths, the same spot size, the same Frie Light of operation, essentially the same fluence levels, and the same intended use as the predicate devices. The Light Age Q-Clear™ Laser does not raise new questions of safety or efficacy, and is substantially equivalent to the predicate devices." This is the core argument for its approval, not a report of meeting specific performance criteria from a new study.

Ask a specific question about this device